A Study of Circulating Tumor DNA as a Biomarker of a Complete Response of Disease for Advanced Gastroesophageal Adenocarcinoma


About this study

The purpose of this study is to evaluate circulating tumor DNA as a potential biomarker for pre-surgery treatment response in patients who have esophageal cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • Age > 18 years
  • Patients that are undergoing combined modality therapy with curative intent for esophageal cancer at Mayo clinic
  • Patients must have been enrolled onto IRB 12-009302 and consented to the use of their tissue for future research

 Exclusion Criteria: 

  • Patients that have a known active malignancy other than esophageal cancer.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Helen Ross, M.D.

Open for enrollment

Contact information:

Regina Becker



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer